High levels of CD47 protein expression have been widely reported across different tumor types and are an independent negative prognostic factor in multiple cancers [8–17], providing a strong rationale for disruption of the CD47/SIRPα axis as a therapeutic intervention. The gene discussed is CD47; the disease is neoplasm.